GB9221657D0 - Recombinant bispecific antibodies - Google Patents

Recombinant bispecific antibodies

Info

Publication number
GB9221657D0
GB9221657D0 GB929221657A GB9221657A GB9221657D0 GB 9221657 D0 GB9221657 D0 GB 9221657D0 GB 929221657 A GB929221657 A GB 929221657A GB 9221657 A GB9221657 A GB 9221657A GB 9221657 D0 GB9221657 D0 GB 9221657D0
Authority
GB
United Kingdom
Prior art keywords
bispecific antibodies
recombinant bispecific
recombinant
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929221657A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCOTGEN Ltd
Original Assignee
SCOTGEN LIMITED
SCOTGEN LTD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCOTGEN LIMITED, SCOTGEN LTD filed Critical SCOTGEN LIMITED
Priority to GB929221657A priority Critical patent/GB9221657D0/en
Publication of GB9221657D0 publication Critical patent/GB9221657D0/en
Priority claimed from GB9507442A external-priority patent/GB2286189A/en
Application status is Pending legal-status Critical

Links

GB929221657A 1992-10-15 1992-10-15 Recombinant bispecific antibodies Pending GB9221657D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB929221657A GB9221657D0 (en) 1992-10-15 1992-10-15 Recombinant bispecific antibodies

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB929221657A GB9221657D0 (en) 1992-10-15 1992-10-15 Recombinant bispecific antibodies
GB9507442A GB2286189A (en) 1992-10-15 1993-10-15 Recombinant specific binding protein
CA 2146854 CA2146854A1 (en) 1992-10-15 1993-10-15 Recombinant specific binding protein
AU52837/93A AU5283793A (en) 1992-10-15 1993-10-15 Recombinant specific binding protein
PCT/GB1993/002133 WO1994009131A1 (en) 1992-10-15 1993-10-15 Recombinant specific binding protein
JP50977793A JPH08505761A (en) 1992-10-15 1993-10-15 Recombinant specific binding protein

Publications (1)

Publication Number Publication Date
GB9221657D0 true GB9221657D0 (en) 1992-11-25

Family

ID=10723495

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929221657A Pending GB9221657D0 (en) 1992-10-15 1992-10-15 Recombinant bispecific antibodies

Country Status (5)

Country Link
JP (1) JPH08505761A (en)
AU (1) AU5283793A (en)
CA (1) CA2146854A1 (en)
GB (1) GB9221657D0 (en)
WO (1) WO1994009131A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739984A1 (en) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
US7973137B1 (en) * 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
EP0894135B1 (en) 1996-04-04 2004-08-11 Unilever N.V. Multivalent and multispecific antigen-binding protein
DE69922159T2 (en) * 1998-01-23 2005-12-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Multipurpose antibody derivatives
DE10021678A1 (en) * 2000-05-05 2002-04-18 Stefan Duebel Recombinant polyspecific antibody constructs, useful for diagnosis and treatment of cancer, comprises three antibody fragments,where at least one comprises a disulfide bridge
CA2417185A1 (en) * 2000-07-25 2002-01-31 Shui-On Leung Multivalent target binding protein
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
EP1867661A1 (en) * 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
CN101952312A (en) * 2007-07-31 2011-01-19 米迪缪尼有限公司 Multispecific epitope binding proteins and uses thereof
WO2009040562A1 (en) * 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
EP2641919A3 (en) * 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
WO2009092806A2 (en) 2008-01-25 2009-07-30 Aarhus Universitet Selective exosite inhibition of papp-a activity against igfbp-4
WO2009155932A2 (en) 2008-06-25 2009-12-30 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
EP3165537A1 (en) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
JP5616428B2 (en) * 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
SG176219A1 (en) * 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN104945509A (en) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
US9588121B2 (en) 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag bispecific antibodies
SG187682A1 (en) * 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibody containing disulfide-stabilized Fv fragment
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
CN107936121A (en) * 2011-05-16 2018-04-20 健能隆医药技术(上海)有限公司 Multi-specific FAB fusion proteins and methods of use
KR101723273B1 (en) * 2011-08-23 2017-04-04 로슈 글리카트 아게 Fc-free antibodies comprising two fab fragments and methods of use
PL2802607T3 (en) * 2012-01-13 2018-03-30 Julius-Maximilians-Universität Würzburg Dual antigen-induced bipartite functional complementation
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
ES2597228T3 (en) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedure for the selection and production of objectification entities, as targets, highly selective and multispecific, custom, which contain at least two different binding entities, and use thereof
JP2016536326A (en) 2013-08-29 2016-11-24 ユニバーシティ オブ コペンハーゲン Anti-adam12 antibody for the treatment of cancer
KR20160134668A (en) 2014-03-14 2016-11-23 노파르티스 아게 Antibody molecules to lag-3 and uses thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP2017527271A (en) 2014-07-21 2017-09-21 ノバルティス アーゲー Treatment of cancer using human anti bcma chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US20170211055A1 (en) 2014-07-21 2017-07-27 Novartis Ag Sortase synthesized chimeric antigen receptors
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
AU2015317608A1 (en) 2014-09-17 2017-04-06 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015333687A1 (en) 2014-10-14 2017-04-27 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3271402A1 (en) 2015-03-16 2018-01-24 Aarhus Universitet Antibodies towards an extracellular region of nbcn1
RU2017134652A (en) 2015-04-08 2019-04-09 Новартис Аг Cd20 therapy, CD22 therapy, and combination therapy with cells expressing the chimeric antigen receptor (car) k cd19
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3317301A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
AU2016369623A1 (en) 2015-12-17 2018-06-28 Novartis Ag Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
BR112018012138A2 (en) 2015-12-17 2018-12-04 Novartis Ag antibody molecules for PD-1 and uses thereof
EP3405492A1 (en) 2016-01-21 2018-11-28 Novartis AG Multispecific molecules targeting cll-1
KR20180118175A (en) 2016-03-04 2018-10-30 노파르티스 아게 Cells expressing multiple chimeric antigen receptor (CAR) molecules and their uses
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
SG11201809041TA (en) 2016-04-15 2018-11-29 Novartis Ag Compositions and methods for selective protein expression
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP3491016A1 (en) 2016-07-28 2019-06-05 Novartis AG Combination therapies of chimeric antigen receptors and pd-1 inhibitors
WO2018026819A2 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
KR20190057366A (en) 2016-10-07 2019-05-28 노파르티스 아게 Chimeric antigen receptor for the treatment of cancer
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IL97459D0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins

Also Published As

Publication number Publication date
JPH08505761A (en) 1996-06-25
WO1994009131A1 (en) 1994-04-28
AU5283793A (en) 1994-05-09
CA2146854A1 (en) 1994-04-28

Similar Documents

Publication Publication Date Title
DE69307495D1 (en) Oligothionukleotide
DE69316369D1 (en) Oligonukleotid alkylphosphonothiate
DE69310146D1 (en) Riemenspannvorreichtung
DE69319731D1 (en) Wässrige polyurethan-dispersionen
DE69320476D1 (en) Erythromycinderivate
GB2269063B (en) Auto-reclosers
GB2257145B (en) Recombinant antibodies specific for TNFalpha
GB2246781B (en) CD3 specific recombinant antibody
GB2269176B (en) Peptides
HU9303423D0 (en) Catechin-diether-type pdeiv-inhibitors
HU9303515D0 (en) Pyrrolo-pyrimidines
HU9303579D0 (en) Resin-free-succinimides
HU9300184D0 (en) Amin-oxides
HU9203484D0 (en) Humanized and chimaeric type antibodies
DE69313449D1 (en) Akarizid
PL175111B1 (en) Novel taxoides
IL128406D0 (en) Monoclonal antibodies
AU6934294A (en) Humanised antibodies
GR3033095T3 (en) Anti-gp39 antibodies and uses therefor
PL314908A1 (en) Humanised antibodies and their application
GB9322501D0 (en) Fusion peptides with binding for streptavidin
IL103560D0 (en) Stabilised antibodies
DE69306746D1 (en) Schlichtmittelzusammensetzung
GB9206757D0 (en) Novel peptide receptor ligands
DE69330517D1 (en) Trachealtubus mit flexiblem segment